Clinical TrialsSearch results
Number of results: 341
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Randomized phase III study of Standard CHOP(S-CHOP) versus Biweekly CHOP(Bi-CHOP) in aggressive Non-Hodgkin's Lymphoma(JCOG9809)
- Non-Hodgkin's lymphoma
- Japan Clinical Oncology Group(JCOG)
- 2005-08-04
Other
- Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)
- CD20 positive diffuse large B cell lmyphoma
- Japan Clinical Oncology Group(JCOG)
- 2007-12-04
Other
- Randomized phase II study of the Induction Chemotherapy with Docetaxel alone vs CDDP+Docetaxel for c-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)
- pulmonary neoplasm
- Japan Clinical Oncology Group(JCOG)
- 2005-07-28
Other
- Randomiazed controlled trial comparing docetaxel-cisplatin combination with docetaxel alone in elderly patients with advanced non-small-cell lung cancer(JCOG0803/WJOG4307L)
- non-small-cell lung cancer
- Japan Clinical Oncology Group(JCOG)
- 2008-10-10
Other
- Phase III trial of doxorubicin / cyclophosphamide (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
- Patients with Metatatic Breast Cancer
- Japan Clinical Oncology Group(JCOG)
- 2005-09-12
Other
- Phase III study of VCAP-AMP-VECP vs. biweekly CHOP in aggressive adult T-cell leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.
- adult T-cell leukemia / lymphoma
- Japan Clinical Oncology Group(JCOG)
- 2005-08-17
Other
- Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)
- previouly untreated advanced stage Hodgkin lymphoma (stage II, III, IVy)
- Japan Clinical Oncology Group(JCOG)
- 2005-08-30
Other
- Phase II study of ABV with increased dose of adriamycin (ADM) and deleted DTIC followed by adjuvant involved-field radiotherapy (ABV/IFRT) to residual or initial bulky tumor for the previously untreated patients with advanced Hodgkin's disease (stage IB, IIB, III, IV or bulky). (JCOG9705)
- previouly untreated advanced stage Hodgkin lymphoma (stage IB, IIB, III, IV, or bulky)
- Japan Clinical Oncology Group(JCOG)
- 2005-08-18
Other
- Docetaxel(D) versus docetaxel plus gemcitabine(DG) for second-line treatment of non-small cell lung cancer (NSCLC) : Results of a JCOG randomized trial (JCOG0104)
- Non-small cell Lung Cancer
- Japan Clinical Oncology Group(JCOG)
- 2005-07-22
Other
- CHOP therapy for low and low-intermediate risk patients of advanced aggressive non-Hodgkin's lymphoma (JCOG9508, LSG17(CHOP))
- low and low-intermediate risk of aggressive non-Hodgkin's lymphoma
- Japan Clinical Oncology Group(JCOG)
- 2005-08-09